Goodbody Health Inc.

Symbol | Ccy Code | Bid | Ask | Share Price (Mid) | Previous Close | Volume | Last Traded |
---|---|---|---|---|---|---|---|
GDBY | GBX | 1.2 | 1.5 | 1.35 | 1.35 | 30000 | 24.06.22 |
MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.
Financial Information
Performance
Earnings per share of -2.87p for 12/2020 has grown from -4.77p in 12/2019 or 40% over the period.
Earnings per share
% growth (1)
12/2020 -40%
Average over 2 periods+ -20%
LowHigh
(1) % growth is year on year % change in EPS.
Basic earnings per share are earnings from continuing and discontinued operations that are attributable to current equity holders.
Earnings per share of -2.87p for 12/2020 has grown from -4.77p in 12/2019 or 40% over the period.
Earnings per share | % growth (1) | |
---|---|---|
12/2020 | -40% | |
Average over 2 periods+ | -20% |
(1) % growth is year on year % change in EPS.
Basic earnings per share are earnings from continuing and discontinued operations that are attributable to current equity holders.
Business Insight
Costs to Revenues ratio of 3.1 in 12/2020 has declined from 3 in 12/2019. Operating costs over the period have increased at a faster pace than the Revenues have increased.
Cost to Revenue ratio (2)
Multiple to Revenue
12/2019 3.0x
12/2020 3.1x
Average multiple over 2 periods+ 3.0x
LowHigh
(2) Costs include selling and admin, depreciation, amortisation and other operating costs.
Costs to Revenues ratio of 3.1 in 12/2020 has declined from 3 in 12/2019. Operating costs over the period have increased at a faster pace than the Revenues have increased.
Cost to Revenue ratio (2) | Multiple to Revenue | |
---|---|---|
12/2019 | 3.0x | |
12/2020 | 3.1x | |
Average multiple over 2 periods+ | 3.0x |
(2) Costs include selling and admin, depreciation, amortisation and other operating costs.
Valuation
Financial Metric
Price multiple to metric
Relationship strength between metric and share price ±
EBITDA -3.2x
EBIT -2.9x
NI -3.1x
FCF -5.7x
DPS -
Assets 1.8x
CE 2.2x
Financial Metric | ||
---|---|---|
EBITDA | -3.2x | |
EBIT | -2.9x | |
NI | -3.1x | |
FCF | -5.7x | |
DPS | - | |
Assets | 1.8x | |
CE | 2.2x |
The Relationship Strength is statistical measure of how close the data is to a line of best-fit line between share price and the metric shown. It is scaled between zero (no relationship) and 5 (strong relationship).
+ In cases of change in accounting period length, the average is for the last 3 periods. In all cases, it is dependent on published available data and may be for periods shorter than 3 years
± The ‘Strength’ bar shows the strength of the statistical linear relationship of the metrics shown in the chart over the last three periods of data.
Click here to download a glossary of terms.
All data provided by Fregnan.
Last results date: 31.12.20 | |
---|---|
Enterprise Value | £14.57m |
EV/EBITDA | (3.19) |
EV/EBIT | (2.89) |
PE Ratio | (1.45) |
PEG | - |
Dividend Yield | - |
Free Cash Yield | (37.96)% |
Click here to download a glossary of terms.
All data provided by Fregnan.
31.12.19 (£'000) |
31.12.20 (£'000) |
|
---|---|---|
Income Statement | ||
Revenue | 1,449 | 1,994 |
Operating Income (EBIT) | (3,553) | (5,042) |
Net Income | (3,798) | (4,659) |
Balance Sheet | ||
Cash | 1,993 | 1,289 |
Total Debt | 621 | 500 |
Total Liabilities | 1,050 | 1,925 |
Total Equity | 3,501 | 6,284 |
Operating Margin | (245.12)% | (252.85)% |
EPS - Basic | (4.77)p | (2.87)p |
EPS - Growth | - | (39.88)% |
Dividend Per Share | - | - |
Average Shares Outstanding | 79.60m | 162.45m |
ROA | - | (73.01%) |
ROCE | - | (94.08%) |
ROE | - | (95.22%) |
Click here to download a glossary of terms.
All data provided by Fregnan.
31.12.19 (£'000) |
31.12.20 (£'000) |
|
---|---|---|
Revenue | 1,449 | 1,994 |
Cost of Revenue | 695 | 871 |
Depreciation & Amortisation | 260 | 471 |
Gross Profit | 495 | 652 |
Other Operating Expenses | 4,048 | 5,695 |
Operating Income (EBIT) | (3,553) | (5,042) |
Net Interest Expense | 11 | - |
Unusual Expense (incl. Exceptionals) | 233 | (48) |
Non-Operating Expense | - | 208 |
Profit (pre-tax) | (3,798) | (4,787) |
Taxation | - | 128 |
Other Expenses and Minortity Interest | - | - |
Net Income | (3,798) | (4,659) |
Click here to download a glossary of terms.
All data provided by Fregnan.
31.12.19 (£'000) |
31.12.20 (£'000) |
|
---|---|---|
Cash from Operations | (2,613) | (2,348) |
Cash from Investing | (493) | 2,412 |
Cash from Financing | 1,356 | (184) |
Other Miscellaneous | - | - |
Net Cash Flow | (1,750) | (120) |
Click here to download a glossary of terms.
All data provided by Fregnan.
31.12.19 (£'000) |
31.12.20 (£'000) |
|
---|---|---|
Current Assets | 2,700 | 2,888 |
Non-Current Assets | 1,851 | 5,321 |
Total Assets | 4,552 | 8,210 |
Current Liabilities | 600 | 1,442 |
Non-Current Liabilities | 451 | 483 |
Total Liabilities | 1,050 | 1,925 |
Net Assets | 3,501 | 6,284 |
Total Equity | 3,501 | 6,284 |
Click here to download a glossary of terms.
All data provided by Fregnan.
Address
Business Address
Goodbody Health Inc., The Blue Building, Stubbs Lane, Beckington Frome, Somerset, BA11 6TE, United Kingdom.
Email: enquires@goodbodyhealth.com
Phone: +44 (0) 20 7971 1255
Registered Address
1055 West Georgia Street, 1500 Royal Centre, PO Box 11117, Vancouver, BC, V6E 4N, Canada.
Contacts
Corporate Adviser
Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, United Kingdom.
Email: info@pcorpfin.com
Phone: +44 (0)20 7469 0930
Registrar
Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS13 8AE, United Kingdom.
Email: web.queries@computershare.co.uk
Phone: 0370 703 6191